Cognitive disorders such as depression, anxiety, and senescent-induced memory loss are a growing pandemic in the world. Anxiety is the most common psychiatric disorder in America, affecting upwards of 50 million people a year; depression has a lifetime prevalence of 20% of the population, and it\u27s predicted pathological memory disorders such as Alzheimer\u27s disease (AD) will reach exponential levels by the year 2050. While there are treatments for anxiety and depression, far less success has been reached with therapeutics for AD. Phosphodiesterases (PDEs) may be a potential novel target for future therapeutics aimed at combatting these psychiatric illnesses and neurodegenerative diseases. PDEs are a super family of 11 smaller enzyme ...
Cyclic nucleotide phosphodiesterases (PDEs) are a super-family of enzymes that regulate intracellula...
Alzheimer's disease (AD) is characterized by progressive cognitive deficits and synaptic dysfunction...
Phosphodiesterase type 4D (PDE4D) has been indicated as a promising target for treating neurodegener...
Cognitive disorders such as depression, anxiety, and senescent-induced memory loss are a growing pan...
Cognitive dysfunction is a core feature of dementia and a prominent feature in psychiatric disease. ...
Cognitive dysfunction is a core feature of dementia and a prominent feature in psychiatric disease. ...
3'-5'-Cyclic adenosine monophosphate (cAMP) is known to be an important regulator of synaptic plasti...
IntroductionThe second messengers cAMP and cGMP mediate fundamental aspects of brain function releva...
Phosphodiesterase inhibitors (PDE-Is) enhance cAMP and/or cGMP signaling via reducing the degradatio...
RATIONALE: One of the major complaints most people face during aging is an impairment in cognitive f...
Phosphodiesterases (PDEs) are the only superfamily of enzymes that have the ability to break down cy...
Abstract Background PDE4 cyclic nucleotide phosphodiesterases regulate 3′, 5′ cAMP abundance in the ...
Phosphodiesterase 11A (PDE11A) is the most recently identified family of phosphodiesterases (PDEs), ...
Phosphodiesterase type 4 inhibitors (PDE4-Is) have received increasing attention as cognition-enhanc...
Phosphodiesterases (PDE) are enzymes responsible for terminating cyclic nucleotide signaling. Neurop...
Cyclic nucleotide phosphodiesterases (PDEs) are a super-family of enzymes that regulate intracellula...
Alzheimer's disease (AD) is characterized by progressive cognitive deficits and synaptic dysfunction...
Phosphodiesterase type 4D (PDE4D) has been indicated as a promising target for treating neurodegener...
Cognitive disorders such as depression, anxiety, and senescent-induced memory loss are a growing pan...
Cognitive dysfunction is a core feature of dementia and a prominent feature in psychiatric disease. ...
Cognitive dysfunction is a core feature of dementia and a prominent feature in psychiatric disease. ...
3'-5'-Cyclic adenosine monophosphate (cAMP) is known to be an important regulator of synaptic plasti...
IntroductionThe second messengers cAMP and cGMP mediate fundamental aspects of brain function releva...
Phosphodiesterase inhibitors (PDE-Is) enhance cAMP and/or cGMP signaling via reducing the degradatio...
RATIONALE: One of the major complaints most people face during aging is an impairment in cognitive f...
Phosphodiesterases (PDEs) are the only superfamily of enzymes that have the ability to break down cy...
Abstract Background PDE4 cyclic nucleotide phosphodiesterases regulate 3′, 5′ cAMP abundance in the ...
Phosphodiesterase 11A (PDE11A) is the most recently identified family of phosphodiesterases (PDEs), ...
Phosphodiesterase type 4 inhibitors (PDE4-Is) have received increasing attention as cognition-enhanc...
Phosphodiesterases (PDE) are enzymes responsible for terminating cyclic nucleotide signaling. Neurop...
Cyclic nucleotide phosphodiesterases (PDEs) are a super-family of enzymes that regulate intracellula...
Alzheimer's disease (AD) is characterized by progressive cognitive deficits and synaptic dysfunction...
Phosphodiesterase type 4D (PDE4D) has been indicated as a promising target for treating neurodegener...